Could a simple pill combo stop deadly rebleeds in cirrhosis?
NCT ID NCT07465471
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding midodrine to the standard drug carvedilol can prevent early rebleeding in people with cirrhosis who have had a variceal bleed. About 210 high-risk patients will receive either carvedilol alone or carvedilol plus midodrine for 6 weeks. The goal is to see if the combination reduces the chance of another bleed and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carvedilol and midodrine
What this could lead to
If it works, this could offer a simple, oral drug combination to reduce dangerous early rebleeding in cirrhosis patients, potentially improving survival without needing complex procedures.
What could go wrong
This is a small, early-stage trial (210 people) that hasn't started recruiting yet. The benefit may be modest, and side effects like low blood pressure or slow heart rate could limit use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, 110070, India
Contact Phone: •••-•••-•••• Email: •••••@•••••